醋酸氟轻松在非感染性后葡萄膜炎治疗中的应用——2024年欧洲专家共识解读  

The clinical application of fluocinolone acetonide in the management of non-infectious posterior uveitis:interpretation of the European Expert Consensus 2024

作　　者：邵毅 李宣仪 韦芊 SHAO Yi;LI Xuanyi;WEI Qian(Department of Ophthalmology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;Department of Epidemiology,Columbia University Mailman School of Public Health,New York 10032,United States of America;Department of Ophthalmology,Imperial College of Science,Technology and Medicine,London SW72AZ,The United Kingdom of Great Britain and Northern Ireland)

机构地区：[1]上海交通大学医学院附属第一人民医院眼科,上海市200080 [2]哥伦比亚大学流行病学系,美国纽约市10032 [3]帝国理工大学眼科学系,英国伦敦市SW72AZ

出　　处：《眼科新进展》2025年第4期253-256,共4页Recent Advances in Ophthalmology

基　　金：国家自然科学基金项目(编号:82160195,82460203);中国医药教育协会科技攻关重点项目(编号:2024KTZ038)。

摘　　要：非感染性后葡萄膜炎(NIU-PS)是一种眼部炎症性疾病,如炎症反复发作且未经有效控制,可能导致眼结构损伤并威胁视力。持续的疾病控制和预防复发是治疗的主要目的。近年来,醋酸氟轻松(FAc)玻璃体内注射作为局部治疗的新选择受到关注,如何实现标准化的炎症管理成为眼科临床工作者的重要议题。本文将对NIU-PS患者接受0.2μg·d^(-1)FAc注射治疗的欧洲专家共识进行解读。Non-infectious posterior uveitis(NIU-PS)is an ocular inflammatory disease that can cause eye structural damage and vision loss if inflammation reoccurs and is not effectively controlled.Achieving sustained disease control and preventing relapses are the primary therapeutic objectives.Recently,fluocinolone acetonide(FAc)intravitreal implants have received attention as a new local treatment option.Standardizing inflammation management has become a critical concern for ophthalmologists.This paper provides a detailed interpretation of the European expert consensus on the use of 0.2μg·d^(-1)FAc intravitreal implants for the treatment of NIU-PS patients.

关 键 词：非感染性后葡萄膜炎 醋酸氟轻松玻璃体内注射 治疗 共识 

分 类 号：R773.9[医药卫生—眼科]